Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 2,257,132 |
|
|||||
| News | - | ||||||
| Day High | 83.09 | Low High |
|||||
| Day Low | 80.90 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| BioMarin Pharmaceutical Inc | BMRN | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -1.26 | -1.53% | 80.91 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 82.03 | 80.90 | 83.09 | 80.91 | 82.17 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 30,921 | 2,257,132 | US$ 81.83 | US$ 184,694,825 | - | 76.02 - 99.56 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:48:20 | 1 | US$ 80.89 | USD |
BioMarin Pharmaceutical (BMRN) Options Flow Summary
BioMarin Pharmaceutical Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 15.26B | 188.68M | - | 2.42B | 167.65M | 0.89 | 91.05 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
BioMarin Pharmaceutical News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMRN Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 89.67 | 93.015 | 80.90 | 85.76 | 2,673,105 | -8.76 | -9.77% |
| 1 Month | 86.98 | 93.36 | 80.90 | 88.08 | 1,751,258 | -6.07 | -6.98% |
| 3 Months | 87.91 | 94.15 | 80.90 | 87.73 | 1,531,671 | -7.00 | -7.96% |
| 6 Months | 81.60 | 99.56 | 76.02 | 88.92 | 1,648,431 | -0.69 | -0.85% |
| 1 Year | 94.67 | 99.56 | 76.02 | 89.21 | 1,416,063 | -13.76 | -14.53% |
| 3 Years | 79.20 | 117.77 | 70.73 | 88.18 | 1,304,684 | 1.71 | 2.16% |
| 5 Years | 84.98 | 131.945 | 62.88 | 86.54 | 1,389,571 | -4.07 | -4.79% |
BioMarin Pharmaceutical Description
| BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) is poised to potentially launch in the 2022-23 timeframe. |
